NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Price Target of $48.90 According to Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $48.90.

Several equities analysts have commented on NAMS shares. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. HC Wainwright reissued a “buy” rating and set a $52.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. Finally, Royal Bank Of Canada lowered their price target on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a research report on Monday, October 5th.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $20.06 on Friday. NewAmsterdam Pharma has a 1 year low of $19.13 and a 1 year high of $42.21. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -9.29 and a beta of 0.10. The firm has a fifty day moving average of $22.86 and a 200-day moving average of $29.83.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. Analysts predict that NewAmsterdam Pharma will post -1.82 EPS for the current year.

Insider Buying and Selling

In related news, CEO Michael H. Davidson acquired 10,000 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was acquired at an average price of $22.65 per share, with a total value of $226,500.00. Following the completion of the transaction, the chief executive officer owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. This represents a 1.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Johannes Kastelein sold 125,000 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the completion of the sale, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 176,846 shares of company stock valued at $4,661,919. Insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV bought a new position in NewAmsterdam Pharma in the first quarter worth $37,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in NewAmsterdam Pharma during the third quarter worth $149,000. PNC Financial Services Group Inc. increased its holdings in NewAmsterdam Pharma by 147.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company’s stock valued at $292,000 after buying an additional 5,437 shares during the period. AlphaCentric Advisors LLC raised its stake in shares of NewAmsterdam Pharma by 6.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock valued at $469,000 after buying an additional 925 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of NewAmsterdam Pharma by 34.6% in the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock valued at $564,000 after buying an additional 4,281 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.